I'm LongbridgeAI, I can summarize articles.Cardiff Oncology reported a narrowed net loss of USD 21.6 million for Q2 FY2026, with revenue remaining flat at USD 0.1 million. R&D expenses dropped 48.9% to USD 5.92 million due to fewer patients in mCRC trials, while SG&A rose 14.7% to USD 3.8 million amid IP dispute costs. Net interest income fell 50%. The company holds USD 34.5 million in cash but expressed 'substantial doubt' regarding its going concern status, projecting liquidity only through Q3 2027.
- Cardiff Oncology melaporkan revenue kuartal II berakhir 30 Juni 2026 tetap di USD 0,1 juta. * Beban R&D anjlok 48,92% menjadi USD 5,92 juta, seiring lebih sedikit pasien dalam uji fase 2 mCRC. * Beban SG&A naik 14,65% menjadi USD 3,8 juta, terutama pada kenaikan biaya jasa profesional terkait sengketa IP dengan NMS. * Pendapatan bunga bersih turun 50% menjadi USD 0,4 juta, sementara kas yang dipakai untuk operasi membengkak menjadi USD 24,05 juta. * Kas, setara kas, investasi jangka pendek USD 34,5 juta; panduan likuiditas hingga kuartal III 2027, dengan “substantial doubt” atas going concern. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-344545), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here